01235 832023
Source Multiple Sclerosis News Today: Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports. The results also show that regeneration is unaffected by treatment with disease-modifying therapies (DMTs), as shown by the levels of a regeneration marker in the brain called growth-associated protein… Read more »
Source Pipeline Review: Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment. The Immune Tolerance Network (ITN) opened the BEAT-MS clinical trial for enrollment. BEAT-MS or “Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS” will investigate high dose immunosuppression followed by AHSCT –… Read more »
Source MS Trust: NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing-remitting MS. In May 2018, NICE carried out a review of several of the MS drugs and decided that Avonex, Extavia, Rebif, Copaxone and Brabio should continue to be available on the NHS in England. At the time, NICE was unable to make a recommendation on… Read more »
Source MS Society: The MS Society went to 10 Downing Street yesterday with their ambassador Janis Winehouse and campaigner Ashley Arundale to deliver a message to the PM: Unfair PIP assessments must change. “More than 21,000 of us have signed an open letter demanding the UK Government makes changes to Personal Independence Payment (PIP). The open… Read more »
Source The Lancet: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource. Methods We… Read more »
Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease. That makes siponimod the first and only oral treatment in Europe specifically for patients with secondary progressive MS with active disease. What was the evidence? The drug approval… Read more »
Source BBC: One in two people who appealed in court against a decision to deny them disability benefits were successful, analysis of five years of data shows. In total, more than 550,000 people won an appeal over their benefits at tribunal between 2013 and 2018. Ann Barker, who has bipolar disorder, said she was tempted to… Read more »
Source MS Society: Virtual reality, wearable robots and magnetic brain stimulation. Technology is at the forefront of 13 new research projects we’ve just announced. Each year we run a competition to choose the best MS research projects from across the UK. This year we’ve committed to raise £1.3 million to fund 13 exciting new research… Read more »
From Multiple Sclerosis News Today A single dose of CD45-ADC, an investigational targeted therapy being developed to treat different types of autoimmune diseases, is enough to reset the normal function of the body’s immune system in a mouse model of multiple sclerosis (MS), and to delay onset of the disease. Those findings were presented earlier… Read more »
Source MS Society: The Advertising Standards Authority (ASA) has upheld our complaint against the Government’s Universal Credit adverts. Formal investigation In June, as part of the Disability Benefits Consortium (DBC), we submitted a complaint to the ASA about the DWP’s advertising campaign in the Metro newspaper. The ads claimed to be a “myth buster” on Universal Credit. But… Read more »